<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994836</url>
  </required_header>
  <id_info>
    <org_study_id>GIS-SUSANTI-TNF-2015</org_study_id>
    <nct_id>NCT02994836</nct_id>
  </id_info>
  <brief_title>GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )</brief_title>
  <official_title>Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a multicentre prospective randomized trial to assess the percentage of
      patients with IBD who, after stopping anti-TNF treatment, have sustained clinical remission
      at one year compared to those in which the treatment is continued at stable doses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre prospective randomized trial.

      Hypothesis:

      The discontinuation of anti-TNF treatment in inflammatory bowel disease (IBD) patients in
      clinical remission is associated with an increased risk of recurrence compared with
      maintaining such treatment.

      Main objective:

      To assess the percentage of patients with IBD who, after stopping anti-TNF treatment, have
      sustained clinical remission at one year compared to those in which the treatment is
      continued at stable doses

      Secondary objectives:

      To compare treatment discontinuation vs. treatment continuation of anti-TNF agents in
      patients with Crohn´s disease or ulcerative colitis in terms of:

        1. remission (relapse-free) time,

        2. phenotype changes with both strategies

        3. mucosal healing,

        4. radiologic healing

        5. impact on quality of life and productivity

        6. safety

        7. to identify relapse predictive factors.

        8. To identify relapse predictive factors after anti-TNF drug discontinuation

        9. Determining the profile of serum cytokines in patients with both strategies, depending
           on drug exposure and if maintained clinical remission or relapse.

      Planned number of subject to be included: 300

      The participation of at 50 hospitals in Spain with an inclusion of about 12 patients per
      hospital is required..

      Case report Form was designed on REDCap (a free, secure, web-based application designed to
      support data capture for research studies).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained clinical remission after one year of follow-up (after discontinuing or continuing treatment with anti-TNF).</measure>
    <time_frame>Change at 12 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical activity assessment</measure>
    <time_frame>Month 0, month 1, month 2, month 4, month 6, month 8, month 10, month 12</time_frame>
    <description>On Crohn´s Disease: Measure by Crohn´s Disease Activity Index (CDAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic activity assessment</measure>
    <time_frame>12 Months. On the Month 0, month 12 or relapse</time_frame>
    <description>On Crohn´s Disease: Measure by Simplified endoscopic activity score for Crohn´s disease (SES-CD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic activity assessment</measure>
    <time_frame>12 Months. Month 0, month 12 or relapse</time_frame>
    <description>Measure by absence of contrast enhancement, edema or presence of ulcers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Month 0, month 1, month 2, month 4, month 6, month 8, month 10, month 12</time_frame>
    <description>Measure by the Inflammatory Bowel Disease Questionnaire (IBDQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Work productivity and activity assessment</measure>
    <time_frame>Month 0, month 1, month 2, month 4, month 6, month 8, month 10, month 12</time_frame>
    <description>Measure by &quot;Spanish Work Productivity and Activity Impairment Questionnaire&quot;.This questionnaire assessments the sum of work time missed because IBD and impairment while working yields the overall work impairment (productivity loss) score. Scores are expressed as percentages of impairment/productivity loss, with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical activity assessment</measure>
    <time_frame>Month 0, month 1, month 2, month 4, month 6, month 8, month 10, month 12</time_frame>
    <description>On the Ulcerative Colitis disease: Measure by Mayo Scoring System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic activity assessment</measure>
    <time_frame>12 Months. On the Month 0, month 12 or relapse</time_frame>
    <description>On the Ulcerative Colitis disease: Measure by Mayo endoscopic score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Anti-TNF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-TNF discontinuation (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-TNF: Infliximab (Infusion)</intervention_name>
    <description>Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)</description>
    <arm_group_label>Anti-TNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-TNF discontinuation: Physiological saline solution</intervention_name>
    <description>Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)</description>
    <arm_group_label>Anti-TNF discontinuation (Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-TNF:Adalimumab (Subcutaneus)</intervention_name>
    <description>Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).</description>
    <arm_group_label>Anti-TNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-TNF discontinuation: Physiological saline solution</intervention_name>
    <description>Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).</description>
    <arm_group_label>Anti-TNF discontinuation (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with IBD (Crohn's disease or ulcerative colitis)

          -  Patients diagnosed with IBD by the usual criteria; both Crohn's and ulcerative colitis
             disease.

          -  Patients older than 18 years.

          -  Have received treatment with an anti-TNF drug to induce clinical remission of IBD by
             clinical practice.

          -  Being the first anti-TNF drug received and the first course of the drug.

          -  In the case of patients with Crohn's disease the indication treatment with anti-TNF it
             must have been for luminal involvement (no perianal).

          -  Are currently in clinical remission.

          -  The pretreatment period with anti-TNF must have been at least 1 year (and with stable
             doses during the last year).

          -  The clinical remission period it must have been at least 6 months.

          -  At the time of inclusion, the patient should be receiving concomitant
             immunosuppressants (thiopurine or methotrexate) to anti-TNF treatment, and must have
             received these immunosuppressive drugs at stable doses for at least the last 3 months.

          -  In patients with Crohn's disease or ulcerative colitis disease, at baseline
             colonoscopy (made up to 3 months before inclusion) should not be &quot;significant&quot;
             injuries.

          -  In the case of patients with Crohn's ileal or ileocolic disease, in magnetic resonance
             whole should not be &quot;significant&quot; injuries.(made up to 3 months before inclusion)

        Exclusion Criteria:

        PRINCIPAL EXCLUSION CRITERIA

          -  Age less than 18 years.

          -  Patients who have been treated with anti-TNF for other indication than the IBD.

          -  Patients who, at some point, have received an anti-TNF drug dose higher than the
             standard, intensified; that is, more than 5 mg / kg / 8 weeks, in the case of
             infliximab, or 40 mg / 2 weeks, in the case of adalimumab.

          -  Patients with Crohn's disease in which the indication for treatment with anti-TNF has
             been the perianal involvement (or luminal and perianal both); or showing active
             perianal disease at the time of inclusion.

          -  Patients who have previously discontinued treatment with anti-TNF and subsequently
             been restarted.

          -  Patients who have previously received it another anti-TNF drug.

          -  Patients with IBD who began treatment with anti-TNF being in clinical remission.

          -  Patients who are not receiving concomitant treatment with immunosuppressants
             (thiopurine or methotrexate) at the moment (and in the previous 3 months).

          -  Patients undergoing bowel resection surgery; therefore, patients who began anti-TNF
             therapy to prevent or treat postoperative recurrence in Crohn's disease will be
             excluded.

          -  Presence of &quot;significant&quot; endoscopic or radiological lesions

          -  Advanced chronic illness or any other condition that prevents the patient from coming
             to the clinic for monitoring or follow-up.

          -  Patients who are pregnant, breastfeeding or intending to become pregnant during the
             course of the study.

          -  Refusal to give consent for participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier MD Perez Gisbert, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Maria Rodriguez</last_name>
    <phone>+34 91 5202540</phone>
    <email>secretariacientifica1@geteccu.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Perez Gisbert, PhD MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005 Apr;128(4):862-9.</citation>
    <PMID>15825070</PMID>
  </reference>
  <reference>
    <citation>Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012 Jan;18(1):174-9. doi: 10.1002/ibd.21792. Epub 2011 Jun 14. Review.</citation>
    <PMID>21674731</PMID>
  </reference>
  <reference>
    <citation>Louis E, Belaiche J, Reenaers C. Anti-TNF and Crohn's disease: when should we stop? Curr Drug Targets. 2010 Feb;11(2):148-51.</citation>
    <PMID>20210763</PMID>
  </reference>
  <reference>
    <citation>Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014 Aug;40(4):338-53. doi: 10.1111/apt.12838. Epub 2014 Jun 23. Review.</citation>
    <PMID>24957164</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D, Nash P, Viladomiu M, Hontecillas R, Bassaganya-Riera J. Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy? Inflamm Bowel Dis. 2014 Apr;20(4):757-66. doi: 10.1097/01.MIB.0000442680.47427.bf. Review.</citation>
    <PMID>24572206</PMID>
  </reference>
  <reference>
    <citation>Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I; IBSEN Study Group. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1430-8.</citation>
    <PMID>18054751</PMID>
  </reference>
  <reference>
    <citation>Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol. 2012 May;47(5):518-27. doi: 10.3109/00365521.2012.660541. Epub 2012 Mar 1.</citation>
    <PMID>22375898</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Marín AC, Chaparro M. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2016 May;111(5):632-47. doi: 10.1038/ajg.2016.54. Epub 2016 Mar 22. Review.</citation>
    <PMID>27002797</PMID>
  </reference>
  <reference>
    <citation>Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1494-502.e1. doi: 10.1016/j.cgh.2013.12.035. Epub 2014 Jan 16.</citation>
    <PMID>24440221</PMID>
  </reference>
  <reference>
    <citation>Bortlík M, Ďuricová D, Lukáš M, Malíčková K, Machková N, Hrdlička L, et al. Infliximab trough levels at treatment discontinuation are associated with increased risk of disease relapse in patients with inflammatory bowel diseases. 20th United European Gastroenterology Week. 2012:P0870.</citation>
  </reference>
  <reference>
    <citation>Guidi L, Ratto C, Semeraro S, Roberto I, De Vitis I, Papa A, Marzo M, Parello A, Foglietto G, Doglietto GB, Gasbarrini GB, Fedeli G. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol. 2008 Jun;12(2):111-7. doi: 10.1007/s10151-008-0411-0. Epub 2008 Jun 10.</citation>
    <PMID>18545878</PMID>
  </reference>
  <reference>
    <citation>Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther. 2005 Dec;22(11-12):1107-13.</citation>
    <PMID>16305724</PMID>
  </reference>
  <reference>
    <citation>Wynands J, Belbouab R, Candon S, Talbotec C, Mougenot JF, Chatenoud L, Schmitz J, Cézard JP, Goulet O, Hugot JP, Ruemmele FM. 12-month follow-up after successful infliximab therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2008 Mar;46(3):293-8. doi: 10.1097/MPG.0b013e31815604cd.</citation>
    <PMID>18376247</PMID>
  </reference>
  <reference>
    <citation>Dart RJ, Griffin N, Taylor K, Duncan J, Sastrillo M, Sanderson J, Irving PM. Reassessment of Crohn's disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal? Frontline Gastroenterol. 2014 Jul;5(3):176-182. doi: 10.1136/flgastro-2013-100392. Epub 2013 Dec 24.</citation>
    <PMID>28839767</PMID>
  </reference>
  <reference>
    <citation>Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31. doi: 10.1053/j.gastro.2011.09.034. Epub 2011 Sep 22.</citation>
    <PMID>21945953</PMID>
  </reference>
  <reference>
    <citation>Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN. Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. World J Gastroenterol. 2012 Sep 28;18(36):5058-64. doi: 10.3748/wjg.v18.i36.5058.</citation>
    <PMID>23049214</PMID>
  </reference>
  <reference>
    <citation>Molnár T, Lakatos PL, Farkas K, Nagy F, Szepes Z, Miheller P, Horváth G, Papp M, Palatka K, Nyári T, Bálint A, Lőrinczy K, Wittmann T. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther. 2013 Jan;37(2):225-33. doi: 10.1111/apt.12160. Epub 2012 Nov 26.</citation>
    <PMID>23181359</PMID>
  </reference>
  <reference>
    <citation>Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014 Jun;20(6):1021-8. doi: 10.1097/MIB.0000000000000052.</citation>
    <PMID>24798636</PMID>
  </reference>
  <reference>
    <citation>Echarri A, Ollero V, Gallego C, Porta A, Castro J. Anti-TNF withdrawal in IBD patients on deep remission. Risk factors of relapse. 20th United European Gastroenterology Week. 2012:P0287.</citation>
  </reference>
  <reference>
    <citation>Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata M, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol. 2007 Oct 21;13(39):5238-44.</citation>
    <PMID>17876895</PMID>
  </reference>
  <reference>
    <citation>Ciria V, Silva P, Leo E, Trigo C, De la Cruz MD, Herrera JM, et al. Factors influencing recurrence following suspension of biological treatment. Importance of mucosal healing. J Crohns Colitis. 2014;8 (suppl.1):P487.</citation>
  </reference>
  <reference>
    <citation>Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. Dig Liver Dis. 2014 Aug;46(8):695-700. doi: 10.1016/j.dld.2014.04.012. Epub 2014 Jun 2.</citation>
    <PMID>24893686</PMID>
  </reference>
  <reference>
    <citation>Ramos L, Hernandez A, Carrillo M, Alonso I, Hernandez N, Quintero E. Outcome of treatment with biological agents in Crohn's disease: 117 patients in 5 years from a tertiary referral center. J Crohns Colitis. 2014;8 (suppl.1):P398.</citation>
  </reference>
  <reference>
    <citation>Luppino I, Spagnuolo R, Marasco R, Cosco C, Ruggiero G, Cosco V, et al. Withdrawal of infliximab (IFX) after achieving remission: outcome in a cohort of inflammatory bowel disease (IBD) patients. Dig Liver Dis. [Conference abstract: Abstracts of the 19th National Congress of Digestive Diseases]. 2013;45S:S100-S1.</citation>
  </reference>
  <reference>
    <citation>Marino M, Zucchi E, Fabbro M, Lodolo I, Maieron R, Vadalà S, et al. Outcome of infliximab discontinuation in IBD patients and therapy rechallenging in relapsers: Single centre preliminary data. J Crohns Colitis. 2014;8 (suppl.1):P401.</citation>
  </reference>
  <reference>
    <citation>Crombé V, Salleron J, Savoye G, Dupas JL, Vernier-Massouille G, Lerebours E, Cortot A, Merle V, Vasseur F, Turck D, Gower-Rousseau C, Lémann M, Colombel JF, Duhamel A. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis. 2011 Oct;17(10):2144-52. doi: 10.1002/ibd.21615. Epub 2011 Feb 1.</citation>
    <PMID>21287665</PMID>
  </reference>
  <reference>
    <citation>Annunziata ML, Papparella LG, Sansoni I, Balestrieri P, Cicala M. Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5 years follow-up. J Crohns Colitis. 2014;8 (suppl.1):P402.</citation>
  </reference>
  <reference>
    <citation>Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC, Millan M, Bailey R, Todoruk D, Cherry R, Teshima CW, Dieleman L, Fedorak RN. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther. 2010 Nov;32(9):1129-34. doi: 10.1111/j.1365-2036.2010.04446.x. Epub 2010 Aug 30.</citation>
    <PMID>20807218</PMID>
  </reference>
  <reference>
    <citation>Nuti F, Conte F, Cavallari N, Civitelli F, Aloi M, Alessandri C, et al. Long term efficacy of infliximab in inflammatory bowel disease at a single tertiary center. Dig Liver Dis. [Congress comunication: 17th National Congress SIGENP]. 2010;42(SUPPL. 5):S326-S7.</citation>
  </reference>
  <reference>
    <citation>Farkas K, Lakatos PL, Nagy F, Szepes Z, Miheller P, Papp M, Palatka K, Bálint A, Bor R, Wittmann T, Molnár T. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol. 2013 Dec;48(12):1394-8. doi: 10.3109/00365521.2013.845906. Epub 2013 Oct 16.</citation>
    <PMID>24131338</PMID>
  </reference>
  <reference>
    <citation>Armuzzi A, Marzo M, Felice C, De Vincentis F, Andrisani G, Moccio G, et al. Long-term scheduled therapy with infliximab in inflammatory bowel disease: a single-centre observational study. Gastroenterology. 2010;238 (suppl.1):S-691.</citation>
  </reference>
  <reference>
    <citation>Muñoz C, Bravo MT, Ortiz de Zárate J, Arreba P, García I, Heras J, et al. Mucosal healing in patients with ulcerative colitis treated with infliximab. What happens after treatment is discontinued? J Crohns Colitis. 2014;8 (suppl.1):P405.</citation>
  </reference>
  <reference>
    <citation>Dai C, Liu WX, Jiang M, Sun MJ. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One. 2014 Oct 20;9(10):e110797. doi: 10.1371/journal.pone.0110797. eCollection 2014.</citation>
    <PMID>25330148</PMID>
  </reference>
  <reference>
    <citation>Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Jauregui-Amezaga A, Rojas-Feria M, et al. Evolution after anti-TNF drug discontinuation in patients with inflammatory bowel disease (IBD): a multicenter long-term follow-up study. J Crohns Colitis. 2015;9 (suppl.1):S329.</citation>
  </reference>
  <reference>
    <citation>Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009 Mar;104(3):760-7. doi: 10.1038/ajg.2008.88. Epub 2009 Jan 27. Review.</citation>
    <PMID>19174781</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015 Aug;42(4):391-405. doi: 10.1111/apt.13276. Epub 2015 Jun 15. Review.</citation>
    <PMID>26075832</PMID>
  </reference>
  <reference>
    <citation>Felice C, Pugliese D, Guidi L, Marzo M, Andrisani G, Papa A, et al. Retreatment with infliximab in inflammatory bowel disease: tolerability and effectiveness of different re-induction regimens. J Crohns Colitis. 2014;8 (suppl.1):P363</citation>
  </reference>
  <reference>
    <citation>Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol. 2013 Mar;36(3):127-46. doi: 10.1016/j.gastrohep.2013.01.002. Epub 2013 Feb 20. Spanish.</citation>
    <PMID>23433780</PMID>
  </reference>
  <reference>
    <citation>D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M; International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European Crohn's and Colitis Organisation (ECCO). Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology. 2012 Dec;143(6):1461-9. doi: 10.1053/j.gastro.2012.09.031. Epub 2012 Sep 20. Review.</citation>
    <PMID>23000597</PMID>
  </reference>
  <reference>
    <citation>Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004 Oct;60(4):505-12.</citation>
    <PMID>15472670</PMID>
  </reference>
  <reference>
    <citation>Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan;132(1):66-75; quiz 432-3. Epub 2006 Oct 12.</citation>
    <PMID>17241860</PMID>
  </reference>
  <reference>
    <citation>Alcalá MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis. 2004 Jul;10(4):383-91.</citation>
    <PMID>15475746</PMID>
  </reference>
  <reference>
    <citation>Vergara M, Montserrat A, Casellas F, Maudsley M, Gallardo O, Ricart E, Calvet X. Validation of the Spanish Work Productivity and Activity impairment questionnaire: Crohn's disease version. Eur J Gastroenterol Hepatol. 2009 Jul;21(7):809-15. doi: 10.1097/MEG.0b013e32830f4c9e.</citation>
    <PMID>19404204</PMID>
  </reference>
  <reference>
    <citation>Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose &quot;escalation&quot; in patients losing response. J Clin Gastroenterol. 2011 Feb;45(2):113-8. doi: 10.1097/MCG.0b013e3181ebaef9.</citation>
    <PMID>21242747</PMID>
  </reference>
  <reference>
    <citation>Brooks AJ, Sebastian S, Cross SS, Robinson K, Warren L, Wright A, Marsh AM, Tsai H, Majeed F, McAlindon ME, Preston C, Hamlin PJ, Lobo AJ. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission. J Crohns Colitis. 2017 Dec 4;11(12):1456-1462. doi: 10.1016/j.crohns.2014.09.007.</citation>
    <PMID>25311864</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>Anti-TNF discontinuation</keyword>
  <keyword>Ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

